CLINICAL_TRIALS
trial_result
· 2021-08-18
Clinical Trial Update: Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients [Phase 2]
Summary
Phase 2 clinical trial evaluating safety, pharmacokinetics, and immunomodulatory effects of AB103 in patients with necrotizing soft tissue infections has comple…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Atox Bio Ltd | Conditions: Necrotizing Soft Tissue Infections | Phase 2 | Status: COMPLETED | Results posted: 2021-08-18